FindTrial
Sign In

Role of Magnesium Sulphate on Delirium after cancer surgery- A Randomized Controlled trial

Role of Magnesium Sulphate on Postoperative Delirium in Oncological surgeries- A Randomized Controlled trial - nil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058995
Enrollment
180
Registered
2023-10-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D099- Carcinoma in situ, unspecified

Interventions

Intervention1: Magnesium Sulphate: Intraoperative Magnesium sulphate infusion Dose- loading dose of 30mg/kg in 10 minutes followed by maintenance dose of 10mg/kg/hr. Maximum dose is 60mg/kg Route- Int

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA I-III duration of surgery- more than 2 hours extubation at the end of surgery

Exclusion criteria

Exclusion criteria: o Patients with preoperative neurocognitive dysfunction o Patients not consenting to the study o Patients who will be sent intubated to ICU o Patients who are allergic to any of the study drugs o Patients with MoCA score less than 26

Design outcomes

Primary

MeasureTime frame
To compare the incidence of postoperative delirium with Magnesium sulphate & placebo in elderly patients in oncological surgeries.Timepoint: preoperative to post operative day 3—

Secondary

MeasureTime frame
Difference in inflammatory markers Difference in optic nerve sheath diameter & correlation with postoperative delirium analgesic requirement intraoperatively length of ICU & hospital stay complicationsTimepoint: preoperative to post operative day 3 or till discharge—

Countries

India

Contacts

Public ContactDr Manisha sahoo

Dr B.R.A.IRCH, AIIMS, New Delhi

brajesh.ratre@gmail.com8696156799

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026